German breast group study: Superior activity for nab-paclitaxel in early breast cancer
Study showing superior activity for nab-paclitaxel vs paclitxel in early breast cancer at San Antonio Breast Cancer Symposium, General Session 2, 4:45 PM CT, Wed, Dec 10th
SAN ANTONIO, TX, USA and Neu-Isenburg/Frankfurt, Germany -- December 10, 2014 -- The German Breast Group (GBG) said nab-paclitaxel (ABRAXANE®) demonstrated significant benefit for patients with early high risk breast cancer when compared to conventional solvent-based paclitaxel. The findings are from the GeparSepto clinical trial sponsored by GBG and conducted together with the German AGO-B study group involving over 1200 patients, which is the largest randomized Phase III study ever completed with nab-paclitaxel and the first one completed in high risk early breast cancer. The results were presented by the coordinating investigator Michael Untch, M.D., Berlin in General Session 2 on December 10th, at the 2014 San Antonio Breast Cancer Symposium.
The study found a statistically significant and clinically meaningful 9% absolute improvement from 29% to 38% (p= END